Vaxcyte (PCVX) Stock Forecast & Price Target

Compare

409 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PCVX Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Vaxcyte

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PCVX Stock 12 Month Forecast

Average Price Target

$90.60

▲(203.01% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Vaxcyte in the last 3 months. The average price target is $90.60 with a high forecast of $137.00 and a low forecast of $50.00. The average price target represents a 203.01% change from the last price of $29.90.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"31":"$31","138":"$138","57.75":"$57.8","84.5":"$84.5","111.25":"$111.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":137,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$137.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":90.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$90.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[31,57.75,84.5,111.25,138],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.02,41.01846153846154,49.01692307692308,57.01538461538462,65.01384615384615,73.0123076923077,81.01076923076923,89.00923076923075,97.00769230769231,105.00615384615384,113.00461538461539,121.00307692307692,129.00153846153844,{"y":137,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.02,37.44923076923077,41.878461538461536,46.30769230769231,50.73692307692308,55.16615384615385,59.59538461538462,64.02461538461537,68.45384615384614,72.88307692307691,77.31230769230768,81.74153846153845,86.17076923076922,{"y":90.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.02,34.32615384615385,35.6323076923077,36.93846153846154,38.244615384615386,39.550769230769234,40.85692307692308,42.16307692307693,43.46923076923077,44.77538461538462,46.081538461538464,47.387692307692305,48.69384615384615,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":76.94,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.59,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.76,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.54,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.29,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.6,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.86,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.32,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.02,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.02,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$137.00

Average Price Target$90.60

Lowest Price Target$50.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Seamus Fernandez

Guggenheim

$160→$116

Buy

287.96%

Upside

Reiterated

08/07/25

Guggenheim Sticks to Their Buy Rating for Vaxcyte (PCVX)Our PT moves to $116 (from $160) as the adult pivotal trial catalyst drives our view; reiterate BUY.

David Risinger

Leerink Partners

$60

Buy

100.67%

Upside

Reiterated

08/07/25

Vaxcyte's Strategic Advancements and Financial Stability Justify Buy Rating

Joseph Stringer

Needham

$90

Buy

201.00%

Upside

Reiterated

08/07/25

Vaxcyte's Strategic Adjustments and Optimized Trials Drive Buy Rating

Tara Bancroft

TD Cowen

$85→$50

Buy

67.22%

Upside

Reiterated

08/07/25

Promising Prospects for Vaxcyte's VAX-31: Strong Adult Trial Results and Strategic Advancements in Infant Studies Reinforce Buy Rating

Salim Syed

Mizuho Securities

―

Buy

―

Reiterated

06/20/25

Vaxcyte vaccine candidates contain aluminum, says MizuhoVaxcyte vaccine candidates contain aluminum, says Mizuho

Carter Gould

Cantor Fitzgerald

―

Buy

―

Reiterated

06/10/25

Vaxcyte (PCVX) Receives a Buy from Cantor Fitzgerald

Jason Gerberry

Bank of America Securities

$137

Buy

358.19%

Upside

Reiterated

05/14/25

Bank of America Securities Sticks to Their Buy Rating for Vaxcyte (PCVX)

Dex Genotek

TR | OpenAI - 4o

―

Hold

―

Reiterated

04/22/25

Chris Shibutani

Goldman Sachs

$138→$100

Buy

234.45%

Upside

Reiterated

04/01/25

Vaxcyte (PCVX) PT Lowered to $100 at Goldman SachsGoldman Sachs analyst Chris Shibutani lowered the price target on Vaxcyte (NASDAQ: PCVX) to $100.00 (from $138.00) while maintaining a Buy rating.

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

03/31/25

Optimistic Outlook for Vaxcyte: Potential for Improved Vaccine Efficacy in Future Trials

Thomas Shrader

BTIG

$160

Buy

435.12%

Upside

Reiterated

03/31/25

Vaxcyte's Promising Vaccine Potential and Market Expansion Drive Buy Rating

Roger Song

Jefferies

$146

Buy

388.29%

Upside

Reiterated

03/31/25

Jefferies on Vaxcyte (PCVX): this data increasing PCVXs fundamental valueJefferies analyst Roger Song reiterated a Buy rating and $146.00 price target on Vaxcyte (NASDAQ: PCVX).

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Seamus Fernandez

Guggenheim

$160→$116

Buy

287.96%

Upside

Reiterated

08/07/25

Guggenheim Sticks to Their Buy Rating for Vaxcyte (PCVX)Our PT moves to $116 (from $160) as the adult pivotal trial catalyst drives our view; reiterate BUY.

David Risinger

Leerink Partners

$60

Buy

100.67%

Upside

Reiterated

08/07/25

Vaxcyte's Strategic Advancements and Financial Stability Justify Buy Rating

Joseph Stringer

Needham

$90

Buy

201.00%

Upside

Reiterated

08/07/25

Vaxcyte's Strategic Adjustments and Optimized Trials Drive Buy Rating

Tara Bancroft

TD Cowen

$85→$50

Buy

67.22%

Upside

Reiterated

08/07/25

Promising Prospects for Vaxcyte's VAX-31: Strong Adult Trial Results and Strategic Advancements in Infant Studies Reinforce Buy Rating

Salim Syed

Mizuho Securities

―

Buy

―

Reiterated

06/20/25

Vaxcyte vaccine candidates contain aluminum, says MizuhoVaxcyte vaccine candidates contain aluminum, says Mizuho

Carter Gould

Cantor Fitzgerald

―

Buy

―

Reiterated

06/10/25

Vaxcyte (PCVX) Receives a Buy from Cantor Fitzgerald

Jason Gerberry

Bank of America Securities

$137

Buy

358.19%

Upside

Reiterated

05/14/25

Bank of America Securities Sticks to Their Buy Rating for Vaxcyte (PCVX)

Dex Genotek

TR | OpenAI - 4o

―

Hold

―

Reiterated

04/22/25

Chris Shibutani

Goldman Sachs

$138→$100

Buy

234.45%

Upside

Reiterated

04/01/25

Vaxcyte (PCVX) PT Lowered to $100 at Goldman SachsGoldman Sachs analyst Chris Shibutani lowered the price target on Vaxcyte (NASDAQ: PCVX) to $100.00 (from $138.00) while maintaining a Buy rating.

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

03/31/25

Optimistic Outlook for Vaxcyte: Potential for Improved Vaccine Efficacy in Future Trials

Thomas Shrader

BTIG

$160

Buy

435.12%

Upside

Reiterated

03/31/25

Vaxcyte's Promising Vaccine Potential and Market Expansion Drive Buy Rating

Roger Song

Jefferies

$146

Buy

388.29%

Upside

Reiterated

03/31/25

Jefferies on Vaxcyte (PCVX): this data increasing PCVXs fundamental valueJefferies analyst Roger Song reiterated a Buy rating and $146.00 price target on Vaxcyte (NASDAQ: PCVX).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vaxcyte

1 Month

xxx

Success Rate

10/15 ratings generated profit

Average Return

+5.25%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +5.25% per trade.

3 Months

xxx

Success Rate

13/22 ratings generated profit

Average Return

+10.94%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 59.09% of your transactions generating a profit, with an average return of +10.94% per trade.

1 Year

Thomas ShraderBTIG

Success Rate

9/15 ratings generated profit

Average Return

+21.99%

reiterated a buy rating 4 months ago

Copying Thomas Shrader's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +21.99% per trade.

2 Years

xxx

Success Rate

15/28 ratings generated profit

Average Return

+74.93%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 53.57% of your transactions generating a profit, with an average return of +74.93% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PCVX Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PCVX has received 12 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PCVX average Analyst price target in the past 3 months is 90.60.

Each month's total comprises the sum of three months' worth of ratings.

PCVX Financial Forecast

PCVX Earnings Forecast

Next quarter’s earnings estimate for PCVX is -$1.24 with a range of -$1.60 to -$0.92. The previous quarter’s EPS was -$1.22. PCVX beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.61% of the time in the same period. In the last calendar year PCVX has Outperformed its overall industry.

No data currently available

PCVX Sales Forecast

Next quarter’s sales forecast for PCVX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. PCVX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.56% of the time in the same period. In the last calendar year PCVX has Preformed in-line its overall industry.

PCVX Stock Forecast FAQ

What is PCVX’s average 12-month price target, according to analysts?

Based on analyst ratings, Vaxcyte, Inc.’s 12-month average price target is 90.60.

What is PCVX’s upside potential, based on the analysts’ average price target?

Vaxcyte, Inc. has 203.01% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PCVX a Buy, Sell or Hold?

Vaxcyte, Inc. has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Vaxcyte, Inc.’s price target?

The average price target for Vaxcyte, Inc. is 90.60. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $137.00 ,the lowest forecast is $50.00. The average price target represents 203.01% Increase from the current price of $29.9.

What do analysts say about Vaxcyte, Inc.?

Vaxcyte, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of PCVX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Vaxcyte (PCVX) Stock Forecast & Price Target

PCVX Analyst Ratings

PCVX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Vaxcyte

PCVX Analyst Recommendation Trends

PCVX Financial Forecast

PCVX Earnings Forecast

PCVX Sales Forecast

PCVX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts